Aventura, FL – March 30, 2019

Aventura, FL US
March 30, 2019

Description

With personalized medicine on the exponential rise, the compounding industry is experiencing significant growth and demand due to its unique ability to customize pharmaceutical preparations meeting patient-specific needs. Along with this growing demand, the successful compounding pharmacist is challenged by a number of operational and clinical parameters of practice.

Some operational challenges manifest themselves as an increase in volume of prescriptions containing the same active pharmaceutical ingredients (APIs) of the same or variable strength. Even the experienced compounding pharmacist may find themselves unable to manage this increased workload. This program employs strategies that address this operational challenge. From a clinical perspective, contemporary compounding oftentimes involves the use of larger and/or lipophilic molecules. The bioavailability of these molecules may present a challenge, as they are not easily absorbed. To compensate, specialized delivery systems can be employed. The abovementioned challenges require a practical skillset and tactical approach that meets prescriber and patient needs and improves practice efficiency and efficacy.

Expanding on the foundational knowledge taught in LP3 Network’s course, “The Science of Pharmaceutical Compounding – Non-Sterile Training” this program delves further into the complexities of managing a more robust non-sterile compounding practice.  In this training, participants will learn how to practically implement a new set of skills and strategies, and then apply them to process development (PD) requirements, stock formulation records (SFRs), master formulation records (MFRs), and compounding records (CRs). With this practical start-to-finish approach, experienced compounders will develop and use a new set of tools needed to make their compounding practice more financially profitable, more time and task efficient during day-to-day operations, and ultimately more reputable in their respective customized therapeutic areas of practice. In order to achieve this goal, the program is divided into a seminar and laboratory component.

SEMINAR COMPONENT

This is a 4-hour interactive seminar which features robust clinical due diligence practices, practical methods to optimize performance, advanced developmental and preparatory techniques, and new technology featuring automated calculations. These advanced tools and skills are applicable to powder blends; liquid-, semisolid-, and solid- filled capsules; semisolids delivered in actuated doses; and solid molded dosage forms.

Featured practical tools include:

  • Preparatory methods, use, application, and automation for:
    • Stock powder blend aliquots
    • Stock powder-in-liquid aliquots and concentrates
    • Stock powder-in-semisolid aliquots and concentrates
  • Specialized and refined preparatory procedures to save time and money
  • Standard operating procedures (SOPs) for newly learned procedures
  • Methods to easily populate a large number of MFRs
  • Optimizing lipid-based delivery systems and self emulsifying drug delivery systems (SEDDS) for oral capsules
  • Selecting synergistic permeation enhancing agent combinations for improved percutaneous absorption of APIs in transdermal dosage forms

LABORATORY COMPONENT

This is a 4-hour hands-on laboratory training where participants will learn how to incorporate stock powder-blend aliquots, and stock powder-in-liquid aliquots and concentrates using novel preparatory techniques, innovative technology, and having made use of automated calculations. Participants will experience labeling requirements for stock aliquots and concentrates. These aliquots and concentrates will be used to compound four dosage forms:

  • Estradiol* 0.00025 g, Estriol* 0.001 g, Progesterone* 0.030 g Topical Cream prepared from a stock powder-in-liquid aliquot and a stock powder-in-liquid concentrate
  • Naltrexone hydrochloride 0.0001 g, Methylcobalamin 0.001 g Oral Troche prepared from a stock powder blend aliquot
  • Piroxicam 0.005 g / 0.48 mL Oral Liquid-Filled Capsule containing a self emulsifying drug delivery system
  • Ketoprofen 0.0075 g / 0.15 mL Transdermal Cream prepared in a synergistic permeation enhancing agent delivery system, calibrated to an actuated volume, and contained in an actuated dose dispensing device

Participants will document key components of easy-to-use SFRs, MFRs, and CRs. Quantitative analyses of stocks and finished preparations will be conducted using automated calculations. Opportunities to perform quantitative and qualitative assessments, particularly for SFRs, will be revealed. Participants will adhere to specialized SOPs related to cutting-edge techniques and technologies.

Note: Formulas are subject to change.

* Drugs that are found on the National Institute for Occupational Safety and Health (NIOSH) list of Antineoplastic and Other Hazardous Drugs in Healthcare Settings will be replaced by non-hazardous drugs. Proper hazardous drug handling techniques and the correct use of personal protective equipment will be covered.

Intended audience


Pharmacists and pharmacy technicians new to non-sterile compounding or with an existing compounding practice.


Learning Objectives

FOR PHARMACISTS & PHARMACY TECHNICIANS

Seminar

  1. Develop strategies to optimize personnel performance and safety, preparatory techniques and strategies, and time management.
  2. Employ strategies resulting in financial savings.
  3. Demonstrate a clinical due diligence process that improves patient outcomes.
  4. Investigate the features and benefits of working with stock powder-blend aliquots and powder-in-liquid aliquots for patient cohorts when preparing personalized medicine.
  5. Apply skills that build connections between process development, stock formulations, master formulations, and compounding records.
  6. Examine the scientific underpinnings of advanced oral and percutaneous drug delivery systems.
  7. Investigate the features and benefits of on-line pharmaceutical calculations to improve accuracy and precision, while minimizing medication errors.
  8. Demonstrate mathematical competencies in advanced pharmaceutical calculations.
  9. Employ novel techniques and technologies that improve the quality, accuracy, and safety of compounded non-sterile preparations.
  10. Employ uniquely designed SOPs to complement an advanced compounding practice.
  11. Demonstrate best practices by using internal and external testing on stocks and finished preparations to demonstrate compliance with, or exceed, compendia standards.
  12. Evaluate the advantages of a more robust patient monitoring and outcome measures recording system leading to further practice growth and development.

Laboratory

  1. Analyze and interpret drug monographs, certificates of analysis (CoA), and safety data sheets (SDS).
  2. Apply good documentation practices for common SOPs; includes garbing, cleaning and disinfection, and balance calibration.
  3. Practice completing key components of SFRs, MFRs, and CRs, including stock labels, ingredient tables, technology specifications, beyond-use dates, storage and packaging conditions, and much more.
  4. Prepare formulations from stocks powder-blend aliquots and stock powder-in-liquid aliquots for patient cohorts.
  5. Prepare formulations from stock concentrates for patient cohorts.
  6. Prepare liquid-filled self-emulsifying drug delivery system capsules.
  7. Prepare an advanced transdermal drug delivery system contained in an actuated dose-dispensing device.
  8. Employ advanced technologies for powder blending, powder-in-liquid mixing, and liquid capsule filling and sealing.
  9. Evaluate stocks and compounded non-sterile preparations through qualitative and quantitative verification protocols; includes the use of on-line pharmaceutical calculations.
  10. Demonstrate the importance of selecting dispensing devices that will maintain formulation integrity, while facilitating proper dosing and ease of administration.

FINANCIAL SUPPORT:

This learning activity has received financial support from MEDISCA Inc. in the form of an educational grant.


 

COPYRIGHT:


The live activity workbook is copyright © 2016 LP3 Network.

Course summary
Available credit: 
  • 8.00 Contact Hours
Event starts: 
03/30/2019 - 8:00am
Event ends: 
03/30/2019 - 5:00pm
LP3 Network Facility
21550 Biscayne Blvd
Suite 300
Aventura, FL 33180
United States
Cost:
$750.00
LP3 Network Facility
21550 Biscayne Blvd
Suite 300
Aventura, FL 33180
United States

Hotel information: 

The preferred hotel accommodation is the Hampton Inn Hallandale Beach Aventura

For reservations, please call 1-888-871-3430 or to book online, click here

Based on Availability. Payment for hotel accommodations is at the expense of the activity participant. 

Hotel Location: 
Hampton Inn Hallandale Beach Aventura
1000 South Federal Highway
Hallandale Beach, FL 33009
United States
MARK FILOSI, BS Pharm, RPh
Compounding Pharmacist and Co-Founder, Family Care Pharmacy
Disclosure: Accreditation Commission for Health Care Surveyor; MEDISCA Consultant

Mr. Filosi is a compounding pharmacist for a thriving non-sterile and sterile practice with over 20 years of experience. He is also a surveyor for the Pharmacy Compounding Accreditation Board (PCAB), a service of the Accreditation Commission for Health Care (ACHC). Additionally, Mr. Filosi is the owner of Family Care Pharmacy in Plant City, Florida, where he is responsible for the sales and marketing of the compounding segment of his business. His compounding practice ranges from non-sterile hormone preparations to high-risk intrathecal preparations.

He graduated cum laude from Fitchburg State College in Fitchburg, Massachusetts, and then went on to graduate cum laude in Pharmacy from Massachusetts College of Pharmacy in Boston, Massachusetts. Today, Mr. Filosi is a preceptor for Florida A & M University, University of Florida and Massachusetts College of Pharmacy.


Editors

NEIL COHEN, BSc
CE Program Developer
Disclosure: MEDISCA, Consultant


Contributor

MARK FILOSI, BS Pharm, RPh
Compounding Pharmacist and Co-Founder, Family Care Pharmacy
Disclosure: Accreditation Commission for Health Care, Surveyor; MEDISCA, Consultant

Accreditation Period

Course opens: 
01/01/2016
Course expires: 
12/31/2021


CANCELLATION AND REFUND POLICY:


A written request must be sent to LP3 Network requesting “Cancellation without Transfer” to an alternate live activity date. If cancellation occurs at greater than or equal to 31 days from the live activity date, then the registrant will receive a 75% refund; 15-30 days a 50% refund; and less than or equal to 14 days no refund.


TRANSFER POLICY:

The transfer policy is only in effect if requested greater than or equal to 14 days prior to the original live activity date. Failure to submit the “Transfer Request” at least 14 days prior to the original live activity date will default to the “Cancellation and Refund Policy”. The transfer policy can only be applied one (1) time. Transfer to a new live activity date must be within the current calendar year. Failure to attend the new live activity will result in no refund and will no longer be transferable. Confirmation of the new activity date is subject to approval by LP3 Network based on the number of available seats within the selected live activity. There are no refunds, returns, or transfers upon purchase of the home study.


 

Price

Cost:
$750.00
Please login to Enroll or Add to Waitlist